Denali Therapeutics Inc. (DNLI) NASDAQ
20.79
+1.25(+6.40%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 2.9B |
| Enterprise Value | 2.73B |
| P/E Ratio | -7.64 |
| PEG Ratio | 0.98 |
| Price/Sales Ratio | 0 |
| Price/Book Ratio | 4.19 |
| Enterprise/Revenue | 0 |
| Enterprise/EBITDA | -5.64 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | March 31, 2026 |
Profitability
| Profit Margin | 0 |
| Operating Margin | 0 |
Management Effectiveness
| Return On Assets | -0.4 |
| Return On Equity | -0.52 |
Income Statement
| Revenue | 0 |
| Revenue/Share | 0 |
| Gross Profit | -11.18M |
| EBITDA | -497.63M |
| Net Income | -512.54M |
| Diluted EPS | -2.97 |
Balance Sheet
| Total Cash | 987.68M |
| Total Cash/Share | 5.29 |
| Total Debt | 40.05M |
| Total Debt/Equity | 0.04 |
| Current Ratio | 9.28 |
| Book Value Per Share | 4.96 |
Price History
| 52-Week Change | 41.91 |
| 52-Week High | 23.77 |
| 52-Week Low | 12.58 |
| Moving Average 50 Days | 19.58 |
| Moving Average 200 Days | 18.11 |
Statistics
| Average Volume | 1.79M |
| Shares Outstanding | 158.71M |
| % Held by Institutions | 84.01 |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
